Extended Input Deadline for USP´s new Chapter on Quality Considerations for Cannabis
Recommendation
19/20 May 2026
All relevant GMP/GACP aspects for Medical Cannabis
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
Following the previously announced elaboration of a new USP chapter <1568> Quality Considerations for Cannabis and Cannabis-derived Products for Clinical Research the input deadline has been extended to 31 July 2022.
USP is requesting early input from stakeholders on the proposed new General Chapter <1568> which is then expected to be published for comment in Pharmacopeial Forum.
More Information is available at the USP Compendial Notices Website.
Related GMP News
23.04.2026EMA publishes Draft Guideline on the Declaration of Active Substances in Herbal Drugs
23.04.2026Plans to reclassify Hexahydrocannabinol
02.04.2026What are the GMP Requirements for Medical Cannabis?
02.04.2026EFSA sets Cannabidiol (CBD) Safety Limit
02.04.2026What are the GMP Requirements for Herbal Medicinal Products?
03.03.2026Can Steam Treatment be used to Decontaminate Cannabis?